RxDoctor Payments Data

Pamela Schwartz

Psychiatric/Mental Health · Warsaw, INNPI 1679639942

Payments from drug & device makers

$1,072in general payments, 2019–2025

Across 52 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$203
  • Otsuka America Pharmaceutical, Inc.$198
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$185
  • Neurocrine Biosciences, Inc.$88
  • AbbVie$83
  • Alkermes, Inc.$71
  • plus $244 from 6 others

What the payments were for

  • Food & beverage$1,02395%
  • Education$495%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,072 in reported general payments places this provider in the 60th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$1,150
Medicare patients
14
Services billed
17

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate53$166,595
IngrezzaValbenazine Tosylate19$163,821
Abilify MaintenaAripiprazole29$75,056
VraylarCariprazine Hcl29$48,317
FetzimaLevomilnacipran Hcl44$35,915
Risperdal ConstaRisperidone Microspheres16$20,328
Lurasidone Hcl87$19,724
Clozapine80$7,992
XanaxAlprazolam13$7,783
Aripiprazole35$7,058
TrintellixVortioxetine Hydrobromide14$6,564
Vilazodone Hcl59$4,686
Buspirone Hcl190$3,511
Divalproex Sodium ErDivalproex Sodium57$3,304
Quetiapine Fumarate ErQuetiapine Fumarate43$3,129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$43$186,92269 claims
Neurocrine Biosciences, Inc.Ingrezza$88$163,82119 claims
AbbVieVraylar, Fetzima$83$84,23273 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$198$75,05629 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$6,56414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Warsaw

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →